candesartan has been researched along with Proteinuria in 52 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to compare the effect of manidipine versus hydrochlorothiazide (HCTZ) in addition to candesartan on the urinary albumin excretion rate (UAER) in hypertensive patients with type II diabetes and microalbuminuria." | 9.12 | Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. ( Corradi, L; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| " We used enalapril, an angiotensin-converting enzyme inhibitor (ACEI) and candesartan, an angiotensin II receptor blocker (ARB), for the control of proteinuria in a case of immunosuppressive treatment (IST)-resistant nephrotic syndrome." | 7.73 | Treatment with candesartan combined with angiotensin-converting enzyme inhibitor for immunosuppressive treatment-resistant nephrotic syndrome after allogeneic stem cell transplantation. ( Hosoi, G; Ikemiya, M; Ishii, T; Noma, H; Osugi, Y; Sako, M; Yamada, H, 2006) |
| "Azilsartan is a strong antihypertensive ARB, but its antiproteinuric effects are not well understood." | 7.01 | Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial. ( Eriguchi, M; Fujisaki, K; Kitazono, T; Nakano, T; Suehiro, T; Tanaka, S; Torisu, K; Tsuchimoto, A; Tsujikawa, H; Tsuruya, K; Yamada, S; Yoshida, H, 2021) |
| " Beginning 8 wk after birth, SHR underwent unilateral nephrectomy and were given vehicle (control), or candesartan at a standard 5 mg/kg per d (T5), high 25 mg/kg per d (T25), or ultrahigh 75 mg/kg per d dosage (T75)." | 5.34 | Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection. ( Dworkin, LD; Gong, R; Rifai, A; Tolbert, EM; Yu, C, 2007) |
| "The reduction in proteinuria induced by lisinopril (11." | 5.14 | [The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ]. ( Gutiérrez Solís, E; Gutiérrez, E; Huerta, A; Morales, E; Praga, M; Segura, J, 2009) |
| "We sought to compare the effect of manidipine versus hydrochlorothiazide (HCTZ) in addition to candesartan on the urinary albumin excretion rate (UAER) in hypertensive patients with type II diabetes and microalbuminuria." | 5.12 | Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. ( Corradi, L; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "The renoprotective effect of candesartan is considered more favorable than amlodipine in the treatment of ADPKD." | 5.11 | Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. ( Higaki, Y; Higashihara, E; Horie, S; Hosoya, T; Kamura, K; Mochizuki, T; Nakayama, T; Nutahara, K; Shimizu, T; Tsuchiya, K; Yamamoto, N, 2005) |
| "Candesartan promotes a complementary antiproteinuric and a small antihypertensive effect after a treatment period of 8 weeks in patients with chronic glomerulonephritis when given in conjunction with an ACEI." | 5.10 | Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition. ( Bader, BD; Berger, ED; Ebert, C; Erley, CM; Risler, T, 2002) |
| "In a private consulting practice setting, the addition of 8 mg of Candesartan in normotensive patients with chronic renal disease and proteinuria receiving an ACEI reduced proteinuria and blood pressure." | 5.10 | Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. ( Fairley, K; Kincaid-Smith, P; Packham, D, 2002) |
| " After 16 weeks, they were randomized into 4 groups (n = 10 each) with comparable proteinuria: (1) control group sacrificed immediately for baseline data, and groups gavaged daily for 8 weeks with (2) placebo, (3) perindopril (1 mg/kg/day), or (4) candesartan (10 mg/kg/day)." | 3.75 | Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system. ( Amann, K; Boor, P; Heidland, A; Lill, M; Sebeková, K, 2009) |
| " We subsequently used full dose ramipril, candesartan and aliskiren under a close monitoring of kidney function and electrolytes and examined the effect on proteinuria, clinical course and tolerability over 12 months." | 3.75 | Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation. ( Amann, K; Frank, H; Freiberger, V; Heemann, U, 2009) |
| "Candesartan doses in excess of the recommended antihypertensive maxima have been reported to lead to greater reductions of proteinuria than the advised doses." | 3.75 | Proteinuria: Increased angiotensin-receptor blocking is not the first option. ( Cravedi, P; Remuzzi, G; Ruggenenti, P, 2009) |
| " We used enalapril, an angiotensin-converting enzyme inhibitor (ACEI) and candesartan, an angiotensin II receptor blocker (ARB), for the control of proteinuria in a case of immunosuppressive treatment (IST)-resistant nephrotic syndrome." | 3.73 | Treatment with candesartan combined with angiotensin-converting enzyme inhibitor for immunosuppressive treatment-resistant nephrotic syndrome after allogeneic stem cell transplantation. ( Hosoi, G; Ikemiya, M; Ishii, T; Noma, H; Osugi, Y; Sako, M; Yamada, H, 2006) |
| "Standard ACEI plus candesartan is more effective in reducing systolic blood pressure and proteinuria than a 50% increase in ACEI dose." | 3.72 | Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure. ( Fairley, KF; Kincaid-Smith, P; Packham, D, 2004) |
| "Time-dependent elevation of MCP-1 expression was dramatically suppressed by treatment with the angiotensin-converting enzyme inhibitor enalapril or the AT1 receptor antagonist candesartan, and was closely associated with effects on proteinuria and glomerular macrophage number." | 3.70 | Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. ( Brenner, BM; Kato, S; Lee, KW; Luyckx, VA; MacKenzie, HS; Ots, M; Troy, JL; Ziai, F, 1999) |
| "Azilsartan is a strong antihypertensive ARB, but its antiproteinuric effects are not well understood." | 3.01 | Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial. ( Eriguchi, M; Fujisaki, K; Kitazono, T; Nakano, T; Suehiro, T; Tanaka, S; Torisu, K; Tsuchimoto, A; Tsujikawa, H; Tsuruya, K; Yamada, S; Yoshida, H, 2021) |
| " The authors randomly assigned 269 patients who had persistent proteinuria (> or =1 g/d) despite 7 wk of treatment with the highest approved dosage of candesartan (16 mg/d) to 16, 64, or 128 mg/d candesartan for 30 wk." | 2.74 | Supramaximal dose of candesartan in proteinuric renal disease. ( Burgess, E; Chiu, A; Muirhead, N; Pichette, V; Rene de Cotret, P; Tobe, S, 2009) |
| "After the double-blind treatment phase, proteinuria was reduced to 1." | 2.71 | Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. ( Delles, C; Fleischmann, EH; Klingbeil, AU; Schmieder, RE; Veelken, R, 2005) |
| "Proteinuria is common following kidney transplantation and affects more than 40% of kidney transplant patients per year." | 2.47 | Causes and consequences of proteinuria following kidney transplantation. ( G-Cosío, F; Suárez Fernández, ML, 2011) |
| "Candesartan cilexetil was considered to be safe even for long-term treatment in renal transplant patients, and effective to protect renal graft function." | 1.38 | Long-term renoprotective effect of candesartan in renal transplant patients. ( Hayashi, T; Ishii, T; Itami, Y; Nishioka, T; Nose, K; Uemura, H; Yasuda, M, 2012) |
| "The regular dose of an angiotensin II type-1 receptor blocker (ARB) in renal transplant patients for hypertension is shown to be safe and effective; however, information on the appropriate dosing of ARBs in renal transplant patients is limited." | 1.37 | Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients. ( Abe, T; Ichimaru, N; Imamura, R; Isaka, Y; Kawada, N; Kitamura, H; Kojima, Y; Kokado, Y; Moriyama, T; Nonomura, N; Okumi, M; Rakugi, H; Takahara, S, 2011) |
| "Gross proteinuria was largely unaffected by (AT1R) blockade and renal function further declined necessitating, initiation of hemodialysis." | 1.36 | Gross proteinuria and subacute renal failure after coronary angiography - a case report of cholesterol crystal embolization. ( Biesenbach, P; Gremmel, T; Hörl, WH; Kain, R; Säemann, MD, 2010) |
| " Beginning 8 wk after birth, SHR underwent unilateral nephrectomy and were given vehicle (control), or candesartan at a standard 5 mg/kg per d (T5), high 25 mg/kg per d (T25), or ultrahigh 75 mg/kg per d dosage (T75)." | 1.34 | Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection. ( Dworkin, LD; Gong, R; Rifai, A; Tolbert, EM; Yu, C, 2007) |
| "Recent immunosuppressive treatments for lupus nephritis have improved renal survival rate, however, there still exists lupus nephritis refractory to these treatments." | 1.33 | Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. ( Kanda, H; Kubo, K; Mimura, T; Sato, K; Tateishi, S; Yamamoto, K; Yonezumi, A, 2005) |
| "We report here a case of type I diabetes mellitus with secondary FGS accompanied by proteinuria 10 months following kidney transplantation." | 1.33 | Secondary focal segmental glomerulosclerosis following kidney transplantation in a patient with type I diabetes mellitus. ( Hosoya, T; Mitome, J; Miyazaki, Y; Tanno, Y; Utsunomiya, Y; Yamaguchi, Y; Yamamoto, H; Yamamoto, I, 2006) |
| "Early proteinuric diabetic nephropathy increases renal expression of the p47phox component of NAD(P)H oxidase and eNOS with increased indices of systemic and renal oxidative/nitrosative stress." | 1.31 | Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. ( Fujita, T; Goto, A; Onozato, ML; Tojo, A; Wilcox, CS, 2002) |
| "Candesartan treatment ameliorated the glomerular morphological findings at six weeks after disease induction." | 1.31 | Fractalkine expression and the recruitment of CX3CR1+ cells in the prolonged mesangial proliferative glomerulonephritis. ( Gejyo, F; Ikezumi, Y; Ito, Y; Kawachi, H; Koike, H; Morioka, Y; Nakamura, T; Nakatsue, T; Natori, Y; Oyanagi, A; Shimizu, F, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (9.62) | 18.2507 |
| 2000's | 40 (76.92) | 29.6817 |
| 2010's | 6 (11.54) | 24.3611 |
| 2020's | 1 (1.92) | 2.80 |
| Authors | Studies |
|---|---|
| Suehiro, T | 1 |
| Tsuruya, K | 1 |
| Yoshida, H | 1 |
| Tsujikawa, H | 1 |
| Yamada, S | 1 |
| Tanaka, S | 1 |
| Tsuchimoto, A | 1 |
| Eriguchi, M | 1 |
| Fujisaki, K | 1 |
| Torisu, K | 1 |
| Nakano, T | 1 |
| Kitazono, T | 1 |
| de Seigneux, S | 1 |
| Courbebaisse, M | 1 |
| Rutkowski, JM | 1 |
| Wilhelm-Bals, A | 1 |
| Metzger, M | 1 |
| Khodo, SN | 1 |
| Hasler, U | 1 |
| Chehade, H | 1 |
| Dizin, E | 1 |
| Daryadel, A | 1 |
| Stengel, B | 1 |
| Girardin, E | 1 |
| Prié, D | 1 |
| Wagner, CA | 1 |
| Scherer, PE | 1 |
| Martin, PY | 1 |
| Houillier, P | 1 |
| Feraille, E | 1 |
| Sebeková, K | 1 |
| Lill, M | 1 |
| Boor, P | 1 |
| Heidland, A | 1 |
| Amann, K | 2 |
| Burgess, E | 1 |
| Muirhead, N | 1 |
| Rene de Cotret, P | 1 |
| Chiu, A | 1 |
| Pichette, V | 1 |
| Tobe, S | 1 |
| de Zeeuw, D | 1 |
| Lambers-Heerspink, H | 1 |
| Robles, NR | 1 |
| Fernandez Carbonero, E | 1 |
| Romero, B | 1 |
| Sánchez Casado, E | 1 |
| Cubero, JJ | 1 |
| Freiberger, V | 1 |
| Heemann, U | 4 |
| Frank, H | 1 |
| Ruggenenti, P | 1 |
| Cravedi, P | 1 |
| Remuzzi, G | 2 |
| Morales, E | 1 |
| Huerta, A | 1 |
| Gutiérrez, E | 1 |
| Gutiérrez Solís, E | 1 |
| Segura, J | 1 |
| Praga, M | 1 |
| Biesenbach, P | 1 |
| Gremmel, T | 1 |
| Hörl, WH | 1 |
| Kain, R | 1 |
| Säemann, MD | 1 |
| Suárez Fernández, ML | 1 |
| G-Cosío, F | 1 |
| Schmaderer, C | 2 |
| Xing, CJ | 1 |
| Anderson, G | 1 |
| Hermans, R | 1 |
| Lutz, J | 2 |
| Baumann, M | 1 |
| Okumi, M | 1 |
| Kawada, N | 1 |
| Ichimaru, N | 1 |
| Kitamura, H | 1 |
| Abe, T | 1 |
| Imamura, R | 1 |
| Kojima, Y | 1 |
| Kokado, Y | 1 |
| Isaka, Y | 1 |
| Rakugi, H | 2 |
| Nonomura, N | 1 |
| Moriyama, T | 1 |
| Takahara, S | 1 |
| Ishii, T | 2 |
| Yasuda, M | 1 |
| Itami, Y | 1 |
| Hayashi, T | 1 |
| Uemura, H | 1 |
| Nose, K | 1 |
| Nishioka, T | 1 |
| Luño, J | 1 |
| Barrio, V | 1 |
| Goicoechea, MA | 1 |
| González, C | 1 |
| de Vinuesa, SG | 1 |
| Gómez, F | 1 |
| Bernis, C | 1 |
| Espinosa, M | 1 |
| Ahijado, F | 1 |
| Gómez, J | 1 |
| Escalada, P | 1 |
| Kuriyama, S | 1 |
| Tomonari, H | 1 |
| Tokudome, G | 1 |
| Horiguchi, M | 1 |
| Hayashi, H | 1 |
| Kobayashi, H | 1 |
| Ishikawa, M | 1 |
| Hosoya, T | 3 |
| Yokota, K | 1 |
| Kishida, M | 1 |
| Ogura, T | 1 |
| Suzuki, J | 1 |
| Otsuka, F | 1 |
| Mimura, Y | 1 |
| Takeda, M | 1 |
| Nakamura, Y | 1 |
| Makino, H | 1 |
| Hollenberg, NK | 1 |
| Zhou, MS | 1 |
| Adam, AG | 1 |
| Jaimes, EA | 1 |
| Raij, L | 1 |
| Tamura, K | 2 |
| Umemura, M | 1 |
| Yano, H | 1 |
| Sakai, M | 1 |
| Sakurai, Y | 2 |
| Tsurumi, Y | 1 |
| Koide, Y | 1 |
| Usui, T | 1 |
| Yabana, M | 1 |
| Toya, Y | 1 |
| Tokita, Y | 1 |
| Umemura, S | 1 |
| Song, JH | 1 |
| Lee, SW | 1 |
| Suh, JH | 1 |
| Kim, ES | 1 |
| Hong, SB | 1 |
| Kim, KA | 1 |
| Kim, MJ | 1 |
| Matsuda, H | 1 |
| Hayashi, K | 1 |
| Homma, K | 1 |
| Yoshioka, K | 1 |
| Kanda, T | 1 |
| Takamatsu, I | 1 |
| Tatematsu, S | 1 |
| Wakino, S | 1 |
| Saruta, T | 2 |
| Kumagai, H | 1 |
| Onami, T | 1 |
| Takimoto, C | 1 |
| Iigaya, K | 1 |
| Kincaid-Smith, P | 2 |
| Fairley, KF | 1 |
| Packham, D | 2 |
| Nutahara, K | 1 |
| Higashihara, E | 1 |
| Horie, S | 1 |
| Kamura, K | 1 |
| Tsuchiya, K | 1 |
| Mochizuki, T | 1 |
| Nakayama, T | 1 |
| Yamamoto, N | 1 |
| Higaki, Y | 1 |
| Shimizu, T | 1 |
| Chang, A | 1 |
| Logar, CM | 1 |
| Finn, LS | 1 |
| Alpers, CE | 1 |
| Seliger, SL | 1 |
| Kanda, H | 1 |
| Kubo, K | 1 |
| Tateishi, S | 1 |
| Sato, K | 1 |
| Yonezumi, A | 1 |
| Yamamoto, K | 1 |
| Mimura, T | 1 |
| Schmieder, RE | 2 |
| Klingbeil, AU | 1 |
| Fleischmann, EH | 1 |
| Veelken, R | 1 |
| Delles, C | 1 |
| Benigni, A | 1 |
| Zoja, C | 1 |
| Tomasoni, S | 1 |
| Campana, M | 1 |
| Corna, D | 1 |
| Zanchi, C | 1 |
| Gagliardini, E | 1 |
| Garofano, E | 1 |
| Rottoli, D | 1 |
| Ito, T | 1 |
| Osugi, Y | 1 |
| Yamada, H | 1 |
| Hosoi, G | 1 |
| Noma, H | 1 |
| Ikemiya, M | 1 |
| Sako, M | 1 |
| Yamamoto, I | 1 |
| Yamamoto, H | 1 |
| Mitome, J | 1 |
| Tanno, Y | 1 |
| Utsunomiya, Y | 1 |
| Miyazaki, Y | 1 |
| Yamaguchi, Y | 1 |
| Risch, K | 1 |
| Liu, S | 1 |
| Antus, B | 1 |
| Roos, M | 1 |
| Ouyang, N | 1 |
| Lehmann, M | 1 |
| Vanecková, I | 1 |
| Kopkan, L | 1 |
| Husková, Z | 1 |
| Vanourková, Z | 1 |
| Schejbalová, S | 1 |
| Cervenka, L | 1 |
| Kramer, HJ | 1 |
| Yu, C | 1 |
| Gong, R | 1 |
| Rifai, A | 1 |
| Tolbert, EM | 1 |
| Dworkin, LD | 1 |
| Chandar, J | 1 |
| Abitbol, C | 1 |
| Montané, B | 1 |
| Zilleruelo, G | 1 |
| Omasu, F | 1 |
| Oda, T | 1 |
| Yamada, M | 1 |
| Yoshizawa, N | 1 |
| Yamakami, K | 1 |
| Miura, S | 1 |
| Kanno, Y | 1 |
| Takenaka, T | 1 |
| Nakamura, T | 4 |
| Suzuki, H | 1 |
| Fogari, R | 1 |
| Corradi, L | 1 |
| Zoppi, A | 1 |
| Lazzari, P | 1 |
| Mugellini, A | 1 |
| Preti, P | 1 |
| Rinaldi, A | 1 |
| Bramlage, P | 1 |
| Thoenes, M | 1 |
| Paar, WD | 1 |
| Bramlage, CP | 1 |
| Krämer, S | 1 |
| Kron, S | 1 |
| Wang-Rosenke, Y | 1 |
| Loof, T | 1 |
| Khadzhynov, D | 1 |
| Morgera, S | 1 |
| Kawachi, H | 3 |
| Shimizu, F | 3 |
| Martini, S | 1 |
| Neumayer, HH | 1 |
| Peters, H | 1 |
| Ohishi, M | 1 |
| Takagi, T | 1 |
| Ito, N | 1 |
| Tatara, Y | 1 |
| Hayashi, N | 1 |
| Shiota, A | 1 |
| Iwamoto, Y | 1 |
| Katsuya, T | 1 |
| Ogihara, T | 1 |
| Honma, H | 1 |
| Ikeda, Y | 1 |
| Kuroyanagi, R | 1 |
| Takano, H | 1 |
| Obata, J | 2 |
| Sato, T | 1 |
| Kimura, H | 2 |
| Yoshida, Y | 2 |
| Hamar, P | 1 |
| Peti-Peterdi, J | 1 |
| Rázga, Z | 1 |
| Kovács, G | 1 |
| Rosivall, L | 1 |
| Ohno, S | 1 |
| Kurokawa, K | 1 |
| Kato, S | 1 |
| Luyckx, VA | 1 |
| Ots, M | 1 |
| Lee, KW | 1 |
| Ziai, F | 1 |
| Troy, JL | 2 |
| Brenner, BM | 2 |
| MacKenzie, HS | 2 |
| Taal, MW | 1 |
| Chertow, GM | 1 |
| Rennke, HG | 1 |
| Gurnani, A | 1 |
| Jiang, T | 1 |
| Shahsafaei, A | 1 |
| Onozato, ML | 1 |
| Tojo, A | 1 |
| Goto, A | 1 |
| Fujita, T | 1 |
| Wilcox, CS | 1 |
| Thurston, H | 1 |
| Berger, ED | 1 |
| Bader, BD | 1 |
| Ebert, C | 1 |
| Risler, T | 1 |
| Erley, CM | 1 |
| Fairley, K | 1 |
| Ito, Y | 1 |
| Morioka, Y | 1 |
| Nakatsue, T | 1 |
| Koike, H | 1 |
| Ikezumi, Y | 1 |
| Oyanagi, A | 1 |
| Natori, Y | 2 |
| Gejyo, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Randomised, Dose Ranging, Multi-Centre, Phase IIIb Study to Evaluate the Efficacy and Safety of High Doses of Candesartan Cilexetil (Atacand®) on the Reduction of Proteinuria in the Treatment of Subjects With Hypertension and Moderate to S[NCT00242346] | Phase 3 | 270 participants | Interventional | 2003-04-30 | Completed | ||
| Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy[NCT00367562] | Phase 4 | 20 participants | Interventional | 1996-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for candesartan and Proteinuria
| Article | Year |
|---|---|
Causes and consequences of proteinuria following kidney transplantation.
Topics: Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Endothelium, Vascular; Graft Rejection; | 2011 |
[Organ protection by angiotensin II receptor blockers].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2004 |
Dual angiotensin II blockade: a promise of enhanced renal protection?
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 2002 |
16 trials available for candesartan and Proteinuria
| Article | Year |
|---|---|
Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Antineoplastic Combined Chemotherapy Protocols; Benzimidazo | 2021 |
Supramaximal dose of candesartan in proteinuric renal disease.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetic N | 2009 |
Long-term antiproteinuric effect of dual renin-angiotensin system blockade.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2009 |
[The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2009 |
Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihy | 2002 |
Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2003 |
The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidaz | 2003 |
Differing anti-proteinuric action of candesartan and losartan in chronic renal disease.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidaz | 2003 |
Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphe | 2005 |
Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2005 |
Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2006 |
Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2007 |
Renal protective effect in hypertensive patients: the high doses of angiotensin II receptor blocker (HARB) study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2007 |
Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2002 |
Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2002 |
33 other studies available for candesartan and Proteinuria
| Article | Year |
|---|---|
Proteinuria Increases Plasma Phosphate by Altering Its Tubular Handling.
Topics: Adult; Albuminuria; Analysis of Variance; Animals; Benzimidazoles; Biphenyl Compounds; Blotting, Wes | 2015 |
Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimid | 2009 |
Drug dosing for renoprotection: maybe it's time for a drug efficacy-safety score?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2009 |
Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation.
Topics: Adult; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; An | 2009 |
Proteinuria: Increased angiotensin-receptor blocking is not the first option.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2009 |
Gross proteinuria and subacute renal failure after coronary angiography - a case report of cholesterol crystal embolization.
Topics: Acute Kidney Injury; Angiotensin II Type 1 Receptor Blockers; Austria; Benzimidazoles; Biopsy; Biphe | 2010 |
AGE formation blockade with aminoguanidine does not ameliorate chronic allograft nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cardiotonic Ag | 2011 |
Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients.
Topics: Adult; Aged; Albuminuria; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Benzimidazo | 2011 |
Long-term renoprotective effect of candesartan in renal transplant patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pres | 2012 |
Role of bradykinin in renoprotective effects by angiotensin II type 1 receptor antagonist in salt-sensitive hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2003 |
In salt-sensitive hypertension, increased superoxide production is linked to functional upregulation of angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Benzimidazoles; Biphenyl Co | 2003 |
Acute renal failure due to cholesterol crystal embolism treated with LDL apheresis followed by corticosteroid and candesartan.
Topics: Acute Kidney Injury; Adrenal Cortex Hormones; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimi | 2003 |
Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2004 |
A rare cause of necrotizing and crescentic glomerulonephritis in a young adult male.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Autoa | 2005 |
Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pres | 2005 |
Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Gene Expression Regul | 2006 |
Treatment with candesartan combined with angiotensin-converting enzyme inhibitor for immunosuppressive treatment-resistant nephrotic syndrome after allogeneic stem cell transplantation.
Topics: Adolescent; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphe | 2006 |
Secondary focal segmental glomerulosclerosis following kidney transplantation in a patient with type I diabetes mellitus.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidaz | 2006 |
Angiotensin type 1 and type 2 receptor blockade in chronic allograft nephropathy.
Topics: Angiotensin Receptor Antagonists; Animals; Apoptosis; Benzimidazoles; Biphenyl Compounds; Chronic Di | 2006 |
Long-term prevention of hypertension and end-organ damage in Ren-2 transgenic rats is achieved only with persistent but not transient AT1 receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Benzimidazoles; Bip | 2007 |
Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2007 |
Angiotensin blockade as sole treatment for proteinuric kidney disease in children.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Angio | 2007 |
Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Disease Models | 2007 |
[Albuminuria: an indicator of cardiovascular risk].
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Antihypertensi | 2007 |
Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Disease Progression; Drug Thera | 2008 |
Renal protective effects of angiotensin II receptor I antagonist CV-11974 in spontaneously hypertensive stroke-prone rats (SHR-sp).
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cereb | 1994 |
Coinhibition of immune and renin-angiotensin systems reduces the pace of glomerulosclerosis in the rat remnant kidney.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cholesterol; D | 1999 |
Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1999 |
Effects of candesartan on the proteinuria of chronic glomerulonephritis.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Arterioles; Benzimidazoles; | 1999 |
Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Base Sequence; | 1999 |
Mechanisms underlying renoprotection during renin-angiotensin system blockade.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Chemokine CCL2 | 2001 |
Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2002 |
Fractalkine expression and the recruitment of CX3CR1+ cells in the prolonged mesangial proliferative glomerulonephritis.
Topics: Animals; Antibodies, Monoclonal; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Chemok | 2002 |